Stifel analyst Annabel Samimy reiterated a Buy rating and $15.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented, “Following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE